Veradermics shares surge after positive VDPHL01 hair loss trial results

11 articles · Updated · MarketWatch · Apr 27

Veradermics stock jumped 16% to $79.01 in premarket trading following Phase 2/3 trial data showing 80-86% of treated patients reported improved hair coverage versus 36% for placebo.
The VDPHL01 oral pill met all primary and key secondary endpoints with robust hair count increases and was generally well tolerated, positioning it as a potential first-in-class FDA-approved treatment in nearly 30 years.
The extended-release formulation aims to reduce cardiovascular risks seen with existing oral minoxidil, marking a significant milestone for both the company and the hair-loss community.

Could this be the first FDA-approved oral therapy to finally solve female pattern hair loss?

Veradermics' stock is soaring, but what hidden risks could threaten its promising 'best-in-class' drug?

How does this pill's tech eliminate the heart risks that have plagued oral minoxidil for decades?

After a 30-year drought in innovation, is this the start of a hair loss treatment gold rush?

Is this new, safer minoxidil pill genuinely better than the cheap versions doctors already prescribe?

Will a 'cash-pay' model make this breakthrough hair loss pill a luxury for the wealthy?